In vitro maturation (IVM) is an alternative form of in vitro fertilization (IVF), whereby the patient receives little or no gonadotropin stimulation and collected oocytes complete their final stages of maturation in the laboratory. It was first described in an animal model (1) and later replicated in a human model, after oocytes collected from unstimulated follicles underwent spontaneous maturation (2). The first live birth was recorded in 1991, after oocyte maturation following collection by ovarian biopsy (3), and then in 1994 using trans-vaginal techniques (4). The primary purpose for IVM treatment is to avoid the adverse outcomes and additional costs associated with the administration of follicle stimulating hormone (FSH). However, IVM also has the potential to overcome other causes of infertility such as gamete donation, FSH resistance, avoiding the effects of an elevated estradiol, and for fertility preservation. It is estimated that more than 3000 children have been born worldwide from this method, and although some clinics routinely perform IVM, it is still considered a research technique. This chapter will explore the patient cohorts, treatment and laboratory protocols, success rates, and birth outcomes reported from around the world in clinics performing IVM, as well as addressing areas in need of further study and future trends for IVM.
|Title of host publication||Handbook of In Vitro Fertilization|
|Editors||David K. Gardner, Carlos Simon|
|Publication status||Published - 18 Jul 2017|